weighted average fixed rate on the forward swap agreements is 5.1%.
The fair value of the forward swap agreements was a liability of $4.9 million as of December 31, 2005.
In February 2001, the Company entered into interest rate swap agreements that effectively converted variable-interest-rate payments on certain leases from a variable to a fixed rate of 6.1%.
These interest rate swap agreements expired at the end of the respective lease terms during 2005.
The fair value of variable to fixed interest rate swaps was a liability of $1.7 million as of December 31, 2004.9.
INTEREST EXPENSE Interest expense, net consisted of the following
## Table 0 ##
10.
SHORT-TERM DEBT Generally, the Company’s short-term borrowings are in the form of commercial paper or bank loans with an original maturity of three months or less.
In November 2004, the Company entered into a Five Year Credit Agreement (the “Credit Agreement”) with the banks, financial institutions and other institutional lenders listed on the respective signature pages thereof (“Lenders”), Citibank, N. A. , as administrative agent for the Lenders (as defined therein), Bank of America, N. A. , as syndication agent, UBS Loan Finance LLC, as documentation agent, and Citigroup Global Markets, Inc.  and Banc of America Securities LLC, as joint lead arrangers and joint book managers.
The Credit Agreement establishes an unsecured revolving credit facility under which the Company may borrow up to $900 million with the option to increase borrowings by an additional $600 million with the concurrence of the Lenders.
Funds borrowed may be used for general corporate purposes, including commercial paper backstop and business acquisitions.
Advances other than competitive bid advances may be repaid without penalty at any time prior to the last day of the Agreement.
Competitive bid advances must be paid at maturity, and may not be prepaid.
The Credit Agreement contains a financial covenant whereby the ratio of (a) pre-tax income from operations from the most recent four fiscal quarters to (b) consolidated interest expense for the most recent four fiscal quarters may not be less than 2.0 to 1 at the end of each fiscal quarter.
The Credit Agreement contains customary representations and warranties and events of default.
Payment of outstanding advances may be accelerated, at the option of the Lenders, should the Company default in its obligations under the Credit Agreement.
In September 2005, the Company entered into a new short-term credit agreement to establish an unsecured revolving credit facility to borrow up to $300 million.
The agreement expired on December 30, 2005.
Funds were used for general corporate purposes.
The new short-term credit facility was entered into because the Company expected borrowings to exceed $900 million for up to three months beginning in early October 2005 due to the retirement of $200 million of 10-year notes in October 2005, refinancing of certain consolidated lease arrangements, recent contributions to the Company’s pension plans, stock repurchases and seasonal working capital needs.
The Company also maintains lines of credit with domestic and international commercial banks, under which it could borrow in various currencies up to approximately $71.1 million and $60.3 million as of December 31, 2005 and 2004, respectively, at the lending banks’ prime commercial interest rates
accordance with the 2014 capital plan, we repurchased 12.9 million shares of common stock on the open market, with an average price of $85.95 per share and an aggregate repurchase price of $1.1 billion.
On April 3, 2014, consistent with our 2014 capital plan, our Board of Directors approved an increase to PNC’s quarterly common stock dividend from 44 cents per common share to 48 cents per common share beginning with the May 5, 2014 dividend payment.
In connection with the 2015 CCAR, PNC submitted its 2015 capital plan, as approved by its Board of Directors, to the Federal Reserve in January 2015.
PNC expects to receive the Federal Reserve’s response (either a non-objection or objection) to the capital plan submitted as part of the 2015 CCAR in March 2015.
For additional information concerning the CCAR process and the factors the Federal Reserve takes into consideration in evaluating capital plans, see the Supervision and Regulation section of Item 1 of this Report.
See the Liquidity Risk Management portion of the Risk Management section of this Item 7 for more detail on our 2014 capital and liquidity actions.
## Table 1 ##
Average Consolidated Balance Sheet Highlights Table 2: Summarized Average Balance Sheet Total assets were $345.1 billion at December 31, 2014 compared with $320.2 billion at December 31, 2013.
The increase from year end 2013 was primarily due to higher interest-earning deposits with banks and loan growth, partially offset by lower investment securities.
Various seasonal and other factors impact our period-end balances, whereas average balances are generally more indicative of underlying business trends apart from the impact of acquisitions and divestitures.
The Consolidated Balance Sheet Review section of this Item 7 provides information on changes in selected Consolidated Balance Sheet categories at December 31, 2014 compared with December 31, 2013.
Average investment securities decreased during 2014 compared with 2013, primarily due to a net decline in average residential and commercial mortgage-backed securities from principal payments, partially offset by an increase in average U. S.  Treasury and government agencies securities, which was largely driven by purchases to enhance our liquidity position.
Total investment securities comprised 20% of average interest-earning assets in 2014 and 22% in 2013.
Average loans grew in 2014, driven by increases in average commercial loans of $6.4 billion and average commercial real estate loans of $3.2 billion.
The overall increase in loans reflected organic loan growth, primarily in our Corporate & Institutional Banking segment.
Loans represented 70% of average interest-earning assets for 2014 and 73% of average interest-earning assets for 2013.
The following table summarizes the number of individuals served by Health Care Services, by major market segment and funding arrangement, as of December 31:
## Table 2 ##
The number of individuals served with commercial products as of December 31, 2007 decreased by 175,000, or 1%, from the prior year.
The number of individuals served with commercial fee-based products as of December 31, 2007 increased by 305,000, or 2%, over 2006 driven by new customer relationships and customers converting from risk-based products to fee-based products, partially offset by employment attrition at continuing customers.
The number of individuals served with commercial risk-based products decreased by 480,000, or 4%, primarily due to a competitive pricing environment and the conversion of individuals to fee-based products.
The number of individuals served by Medicare Advantage products as of December 31, 2007 decreased by 75,000, or 5%, from 2006, primarily due to a decline in participation in private-fee-for-service offerings, while individuals served by standardized Medicare supplement products increased by 125,000, or 5%, due to new customer relationships.
Medicaid enrollment increased 245,000, or 17%, in 2007 primarily due to new customer gains, including 180,000 individuals served under the TennCare program in Tennessee.
OptumHealth OptumHealth provides health, well-being and financial services to people and organizations nationwide through personalized health advocacy and engagement, specialized benefits such as behavioral, dental and vision offerings, and health-based financial services.
OptumHealth revenues of $4.9 billion increased by $579 million, or 13%, over 2006.
This increase was principally driven by an increase in the number of individuals served by several of its specialty benefit businesses and rate increases related to these businesses.
OptumHealth earnings from operations in 2007 of $895 million increased $86 million, or 11%, over 2006 primarily due to the membership growth and rate increases discussed above.
The OptumHealth operating margin declined from 18.6% in 2006 to 18.2% in 2007 due to a continued business mix shift toward higher revenue, lower margin products, partially offset by effective operating cost management.
Ingenix Ingenix offers solutions to a spectrum of health care market participants on a national and international basis, including data management services, software products, publications, consulting and actuarial services, business process outsourcing services, clinical research outsourcing, pharmaceutical data and consulting services, and revenue cycle management solutions.
Ingenix revenues for 2007 of $1.3 billion increased by $348 million, or 36%, over 2006.
This was primarily driven by new business growth in the health information and contract research businesses as well as from businesses acquired since the beginning of 2006.
Ingenix earnings from operations in 2007 were $266 million, up $90 million, or 51%, from 2006.
This increase in earnings from operations was primarily due to growth in the health information and contract research businesses, businesses acquired since the beginning of 2006 and effective operating cost management.
The operating margin
Other income (expense) for fiscal 2015 was income of $685 million as compared to expense of $481 million in fiscal 2014.
The change in fair value of our AmerisourceBergen warrants resulted in recording income of $759 million and $366 million in fiscal 2015 and 2014, respectively.
The increase in fair value was primarily attributed to the change in the price of AmerisourceBergen’s common stock.
In addition, we recorded $20 million and $19 million in fiscal 2015 and 2014, respectively, of other income relating to the amortization of the deferred credit associated with the initial value of the Walgreens warrants.
We have also recorded a loss of $94 million in fiscal 2015 on derivative contracts that were not designated as accounting hedges.
The losses primarily relate to foreign currency forward contracts entered into in consideration of the delivery of foreign cash consideration related to the Second Step Transaction.
Fiscal 2014 results also included a loss of $866 million related to the Alliance Boots call option.
Upon the amendment and immediate exercise of the call option to acquire the remaining 55% ownership of Alliance Boots, we were required to compare the fair value of the amended option with the book value of the original option.
The fair value of the amended option was estimated to be zero based on its valuation as a financial instrument without regard for its strategic value.
The reduction in value was primarily due to the shorter duration of the amended option and the appreciation since the original valuation in the price of Walgreens stock used as partial consideration for the purchase of the remaining 55% ownership interest in Alliance Boots.
Interest was a net expense of $605 million and $156 million in fiscal 2015 and 2014, respectively.
The increase in fiscal 2015 interest expense is primarily due to the notes we issued to fund a portion of the cash consideration payable in connection with the Second Step Transaction and to subsequently refinance substantially all of Alliance Boots’ outstanding borrowings following completion of the Second Step Transaction.
Additionally, in fiscal 2015 we repaid a portion of our long-term debt in advance of its maturity resulting in additional net interest expense of $99 million.
The effective tax rate for fiscal 2015 and 2014 was 19.9% and 42.9%, respectively.
The decrease in the fiscal 2015 effective tax rate as compared to fiscal 2014 is primarily attributable to recording discrete tax benefits related to previously unrecognized capital loss deferred tax assets as a result of recognizing capital gain income from fiscal 2015 and anticipated future period sale-leaseback transactions.
In addition, as a result of our acquisition of the remaining 55% interest in Alliance Boots that we did not previously own, our annual effective tax rate decreased due to incremental foreign source income taxed at lower rates and additional favorable permanent book-tax differences.
Also as a result of the acquisition, we recognized a non-recurring tax benefit that also lowered our annual effective tax rate.
In addition, we recognized other, net discrete tax benefits in the current fiscal year.
RESULTS OF OPERATIONS BY SEGMENT Retail Pharmacy USA As a result of the completion of the Second Step Transaction, the Company ceased recording equity earnings in Alliance Boots as of December 31, 2014.
As such, the fiscal year ended August 31, 2015 includes equity income from Walgreens’ pre-merger 45% interest in Alliance Boots for four months (September through December 2014).

<table><tr><td>For the years ended December 31,</td><td>2005</td><td>2004</td><td>2003</td></tr><tr><td>In thousands of dollars</td><td></td><td></td><td></td></tr><tr><td>Long-termdebt and lease obligations</td><td>$66,324</td><td>$66,005</td><td>$66,283</td></tr><tr><td>Short-termdebt</td><td>23,164</td><td>4,511</td><td>935</td></tr><tr><td>Capitalizedinterest</td><td>-3</td><td>-2,597</td><td>-1,953</td></tr><tr><td>Interestexpense, gross</td><td>89,485</td><td>67,919</td><td>65,265</td></tr><tr><td>Interestincome</td><td>-1,500</td><td>-1,386</td><td>-1,736</td></tr><tr><td>Interestexpense, net</td><td>$87,985</td><td>$66,533</td><td>$63,529</td></tr></table>
<table><tr><td>Year ended December 31</td><td></td><td></td><td colspan="2">Change</td></tr><tr><td>Dollars in millions</td><td>2014</td><td>2013</td><td>$</td><td>%</td></tr><tr><td>Average assets</td><td></td><td></td><td></td><td></td></tr><tr><td>Interest-earning assets</td><td></td><td></td><td></td><td></td></tr><tr><td>Investment securities</td><td>$55,820</td><td>$57,319</td><td>$-1,499</td><td>-3%</td></tr><tr><td>Loans</td><td>199,648</td><td>189,973</td><td>9,675</td><td>5%</td></tr><tr><td>Interest-earning deposits with banks</td><td>19,204</td><td>4,910</td><td>14,294</td><td>291%</td></tr><tr><td>Other</td><td>8,633</td><td>8,443</td><td>190</td><td>2%</td></tr><tr><td>Total interest-earning assets</td><td>283,305</td><td>260,645</td><td>22,660</td><td>9%</td></tr><tr><td>Noninterest-earning assets</td><td>44,548</td><td>45,019</td><td>-471</td><td>-1%</td></tr><tr><td>Total average assets</td><td>$327,853</td><td>$305,664</td><td>$22,189</td><td>7%</td></tr><tr><td>Average liabilities and equity</td><td></td><td></td><td></td><td></td></tr><tr><td>Interest-bearing liabilities</td><td></td><td></td><td></td><td></td></tr><tr><td>Interest-bearing deposits</td><td>$152,814</td><td>$146,000</td><td>$6,814</td><td>5%</td></tr><tr><td>Borrowed funds</td><td>48,817</td><td>40,022</td><td>8,795</td><td>22%</td></tr><tr><td>Total interest-bearing liabilities</td><td>201,631</td><td>186,022</td><td>15,609</td><td>8%</td></tr><tr><td>Noninterest-bearing deposits</td><td>70,108</td><td>66,168</td><td>3,940</td><td>6%</td></tr><tr><td>Other liabilities</td><td>10,768</td><td>11,159</td><td>-391</td><td>-4%</td></tr><tr><td>Equity</td><td>45,346</td><td>42,315</td><td>3,031</td><td>7%</td></tr><tr><td>Total average liabilities and equity</td><td>$327,853</td><td>$305,664</td><td>$22,189</td><td>7%</td></tr></table>
<table><tr><td> (in thousands)</td><td> 2007</td><td> 2006</td></tr><tr><td>Commercial Risk-based</td><td>10,805</td><td>11,285</td></tr><tr><td>Commercial Fee-based</td><td>14,720</td><td>14,415</td></tr><tr><td>Total Commercial</td><td>25,525</td><td>25,700</td></tr><tr><td>Medicare Advantage</td><td>1,370</td><td>1,445</td></tr><tr><td>Medicaid</td><td>1,710</td><td>1,465</td></tr><tr><td>Standardized Medicare Supplement</td><td>2,400</td><td>2,275</td></tr><tr><td>Total Public and Senior</td><td>5,480</td><td>5,185</td></tr><tr><td>Total Health Care Services Medical Benefits</td><td>31,005</td><td>30,885</td></tr></table>

Question: What was the total amount of Average assets Interest-earning assets in 2014? (in million)